kabutan

Meiji Holdings Co., Ltd.(2269) Summary

2269
TSE Prime
Meiji Holdings Co., Ltd.
3,722
JPY
-17
(-0.45%)
Apr 30, 10:51 am JST
23.23
USD
Apr 29, 9:52 pm EDT
Result
PTS
outside of trading hours
3,723.8
Apr 30, 10:51 am JST
Summary Chart Historical News Financial Result
PER
27.6
PBR
1.32
Yield
2.82%
Margin Trading Ratio
5.26
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
3,704 JPY 23.12 USD
Previous Close Apr 28
3,739 JPY 23.48 USD
High Apr 30, 9:59 am
3,744 JPY 23.38 USD
Low Apr 30, 9:13 am
3,692 JPY 23.05 USD
Volume
260,000
Trading Value
0.97B JPY 6.04M USD
VWAP
3713.39 JPY 23.17 USD
Minimum Trading Value
372,200 JPY 2,323 USD
Market Cap
1.05T JPY 6.57B USD
Number of Trades
1,237
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
2,656
1-Year High May 9, 2025
11,842
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 63,500 95,300 1.50
Apr 17, 2026 79,900 93,700 1.17
Apr 10, 2026 83,200 83,800 1.01
Apr 3, 2026 88,800 94,300 1.06
Mar 27, 2026 606,700 110,100 0.18
Company Profile
Meiji Holdings Co., Ltd. was formed through the integration of Meiji Seika and Meiji Dairies. It is the largest company in the confectionery and dairy industries. The company's pharmaceutical business is experiencing rapid growth, and it is expanding globally.
Sector
Foods
Meiji Holdings Co., Ltd. operates in two business segments: Food and Pharmaceuticals. In the Food segment, the company handles a wide range of products including dairy products, confectioneries, nutritional foods, and animal feed, conducting business through numerous subsidiaries and affiliated companies both domestically and internationally. The Pharmaceutical segment focuses primarily on prescription drugs and veterinary medicines, manufacturing and selling these products through domestic and overseas subsidiaries. As a pure holding company, Meiji Holdings is responsible for formulating group-wide strategies and managing operations. Meiji Co., Ltd. is positioned as the core company in the food business, while Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. are the core companies in the pharmaceutical business. The company is also focusing on global expansion, with numerous overseas subsidiaries, particularly in Asia.